Search International and National Patent Collections

1. (WO2018202850) MICROTUBULE-TARGETING DRUGS AS IMMUNE CHECKPOINT INHIBITORS AND METHODS OF SCREENING NOVEL IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCERS AND INFECTIOUS DISEASES

Pub. No.:    WO/2018/202850    International Application No.:    PCT/EP2018/061499
Publication Date: Fri Nov 09 00:59:59 CET 2018 International Filing Date: Sat May 05 01:59:59 CEST 2018
IPC: G01N 33/50
Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
UNIVERSITÉ PAUL SABATIER TOULOUSE III
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Inventors: FOURNIE, Jean-Jacques
MILLEVOI, Stefania
FRANCHINI, Don-Marc
LANVIN, Olivia
Title: MICROTUBULE-TARGETING DRUGS AS IMMUNE CHECKPOINT INHIBITORS AND METHODS OF SCREENING NOVEL IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCERS AND INFECTIOUS DISEASES
Abstract:
The invention is based on the discovery that mRNA encoding various checkpoint proteins such as PD-1 must interact with dynamic microtubules to allow surface expression of these proteins. Any inhibitor of this interaction is therefore a putative immune checkpoint inhibitor that could be suitable for the treatment of cancers and infectious diseases. Accordingly, the present invention relates to using microtubule-targeting drugs as immune checkpoint inhibitor, and a method of screening an immune checkpoint inhibitor comprising a) determining the ability of a test compound to inhibit the interaction of an mRNA sequence encoding for an immune checkpoint protein to a polymerized-tubulin moiety and b) positively selecting the test compound that inhibits said binding.